索引超出了数组界限。
[1] Singh BN. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy[J]. Clin Cardiol,1997,20(7):608-618.
[2] Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation[J]. Circulation,2012,125(2):381-389.
[3] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J]. J Am Coll Cardiol,2014,64(21):e1-e76.
[4] Tse HF, Lam YM, Lau CP, et al. Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation[J]. Clin Exp Pharmacol Physiol,2001,28(5-6):446-450.
[5] Walkey AJ, Hogarth DK, Lip GY. Optimizing atrial fibrillation management: From ICU and beyond[J]. Chest,2015,148(4):859-864.
[6] Lim HS, Hamaad A, Lip GY. Clinical review: clinical management of atrial fibrillation - rate control versus rhythm control[J]. Crit Care,2004,8(4):271-279.
[7] Delle KG, Geppert A, Neunteufl T, et al. Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias[J]. Crit Care Med,2001,29(6):1149-1153.
[8] 陈 诤,刘少稳. 地高辛在心房颤动治疗中的误区[J]. 国际心血管病杂志,2013,40(2):73-75.
[9] Lubitz SA, Yin X, Rienstra M, et al. Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study[J]. Circulation,2015,131(19):1648-1655.
[10] Ullal AJ, Than CT, Fan J, et al. Amiodarone and risk of death in contemporary patients with atrial fibrillation: findings from the retrospective evaluation and assessment of therapies in AF study[J]. Am Heart J,2015,170(5):1033-1041.
[11] Doyle JF, Ho KM. Benefits and risks of long-term amiodarone therapy for persistent atrial fibrillation: a meta-analysis[J]. Mayo Clin Proc,2009,84(3):234-242.
[12] Jong GP, Chang MH, Chang TC, et al. Long-term efficacy and safety of very-low-dose amiodarone treatment for the maintenance of sinus rhythm in patients with chronic atrial fibrillation after successful direct-current cardioversion[J]. Chin Med J(Engl),2006,119(24):2030-2035.
[13] Amerena J, Chen SA, Sriratanasathavorn C, et al. Insights into management of atrial fibrillation in Asia Pacific gained from baseline data from REgistry on cardiac rhythm disORDers(RecordAF-Asia Pacific [AP])registry[J]. Am J Cardiol,2012,109(3):378-382.
[14] Allen LN, Dai D, Thomas L, et al. Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart disease[J]. Am J Cardiol,2015,115(3):316-322.
[15] Zimetbaum P, Ho KK, Olshansky B, et al. Variation in the utilization of antiarrhythmic drugs in patients with new-onset atrial fibrillation[J]. Am J Cardiol,2003,91(1):81-83.
[16] Chun SH, Sager PT, Stevenson WG, et al. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter[J]. Am J Cardiol,1995,76(1):47-50.
[17] Cadrin-Tourigny J, Wyse DG, Roy D, et al. Efficacy of amiodarone in patients with atrial fibrillation with and without left ventricular dysfunction: a pooled analysis of AFFIRM and AF-CHF trials[J]. J Cardiovasc Electrophysiol,2014,25(12):1306-1313.
[18] Shiga T, Wakaumi M, Imai T, et al. Effect of low-dose amiodarone on atrial fibrillation or flutter in Japanese patients with heart failure[J]. Circ J,2002,66(6):600-604.